[Hemodynamic efficacy of modified gelatin in patients with acute blood loss and sepsis].
The paper presents the results of a clinical trial using the new modified gelatin-based drug hemofusin to correct dyshidria in patients with blood loss and sepsis. Based on the findings, the authors provide evidence for the high clinical efficacy of this drug and the expediency of its incorporation into a complex of infusion therapy in this patient contingent.
Kochergina
V V
VV
Vlasenko
A V
AV
Moroz
V V
VV
Evdokimov
E A
EA
Iakovlev
V N
VN
Alekseev
V G
VG
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005780:Gelatin / Q000008:administration & dosage*; D006439:Hemodynamics / Q000502:physiology*; D006470:Hemorrhage / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D020896:Hypovolemia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D010952:Plasma Substitutes / Q000008:administration & dosage*; D018805:Sepsis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D013386:Succinates / Q000008:administration & dosage*; D016896:Treatment Outcome; D055815:Young Adult
D010952:Plasma Substitutes; D013386:Succinates; C060085:succinylated gelatin; D005780:Gelatin